Analysts think HALO stock price could increase by 16%
Feb 04, 2025, 12:25 PM
5.82%
What does HALO do
Halozyme Therapeutics, a San Diego-based biopharmaceutical company, specializes in drug delivery technology and has two proprietary products, Hylenex and XYOSTED, focusing on subcutaneous administration. Founded in 2003, it employs 373 people and partners with other firms for drug-device combinations.
10 analysts think HALO stock price will increase by 15.99%. The current median analyst target is $65.28 compared to a current stock price of $56.28. The lowest analysts target is $53.53 and the highest analyst target is $80.85.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
